Drug intelligence / Profile preview

GL2702 GLARS-NF1

Development stage: Unknown
Lead developer: GL Pharm Tech
Modality: Small Molecules
Administration: Oral

Overview

GL2702 GLARS-NF1 is a controlled-release tablet formulation of tamsulosin hydrochloride developed by GL Pharm Tech. Tamsulosin is an alpha-1 adrenergic receptor antagonist used primarily to treat benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms. The drug works by selectively blocking alpha-1 receptors in the prostate and bladder neck, leading to relaxation of smooth muscle in these areas and improved urine flow. The controlled-release formulation aims to provide more consistent plasma levels and potentially reduce side effects compared to immediate-release formulations[4].

Brand names: Harnal-D
Other names: tamsulosin hydrochloridetamsulosin HCL

Targets

ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)

Beyond the preview

Go deeper on GL2702 GLARS-NF1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GL2702 GLARS-NF1.

Explore the full profile